IgGenix
As a co-founder of IgGenix, Dr. Croote is building upon pivotal work he performed in the laboratory of Dr. Stephen Quake at Stanford University. His Ph.D. research focused on applying mass spectrometry, single-cell transcriptomics, next-generation sequencing, and bioinformatics to better understand a diverse set of diseases and immunological perturbations including food allergies, flu vaccination, dengue infection, and glioblastoma. He is the lead author of a publication in the peer-reviewed journal Science that describes the first characterization of single human IgE B cells and the allergen-specific antibodies they produce. He received his B.S. from Brown University and Ph.D. from Stanford University where he was a National Science Foundation and Stanford Graduate fellow.
IgGenix
IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake’s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau. They work on translating research discoveries into transformative therapies for individuals suffering from allergies.